Group 1 - The company plans to establish a wholly-owned subsidiary in Hainan or Hunan provinces to engage in the cell industry and related mergers and acquisitions [1] - The registered capital of the new subsidiary will be 100 million yuan [1] - This move aims to strengthen the company's positioning in the cell industry and create a second growth curve for the company [1]

Core Viewpoint - The company plans to establish a wholly-owned subsidiary, Kaineng Cell Medical Group Co., Ltd., in Hainan or Hunan Province with a registered capital of 100 million RMB to enhance its presence in the cell industry and pursue industry mergers and acquisitions [1] Group 1 - The subsidiary will focus on cell industry operations and related mergers and acquisitions [1] - The investment will be funded by the company's own resources, and the transaction does not require board approval, nor does it constitute a related party transaction or a major asset restructuring [1] - This initiative aims to strengthen the company's positioning in the cell industry, creating a second growth curve for the company [1]